期刊文献+

LNG-IUD治疗围绝经后期子宫腺肌病92例临床分析

Treatment of 92 Cases of Adenomyosis in Perimenopausal Period with Levonorgestrel-releasing Intrauterine Device
暂未订购
导出
摘要 目的:通过宫腔内放置左炔诺酮宫内节育器(LNG-IUD)治疗围绝经后期子宫腺肌病患者的随访观察,评价其治疗效果。方法:对92例围绝经后期子宫腺肌病并放置LNG-IUD的患者进行3、6、12、24个月随访,观察月经变化、子宫体积、痛经程度、血清CA125水平。结果:本组92例子宫腺肌病患者置入LNG-IUD后,随着随访时间延长痛经明显缓解(P<0.05);月经减少,子宫体积及血清CA125水平明显下降(P<0.05)。结论:LNG-IUD治疗围绝经后期子宫腺肌病患者操作简便,疗效可靠。 Objective:To investigate the clinical effects of levonorgestrel-releasing intrauterine device(LNG-IUD) in the treatment of adenomyosis in perimenopausel period. Methods: A total of 92 patients with adenomyosis in perimenopausal period were treated with LNG-IUD and followed up at the 3rd,6th, 12th,24th month. Change of menses, uterine volume,visual analogue scale (VAS) of dysmenorrhea,the serum CA125 level and degree of satisfaction with the treatment were observed. Results:The dysmenorrhea was alleviated along with the foliow-up time in all of the patients after insertion of the LNG-IUD ( P〈0.05). The menstrual volume, uterine volume and serum CA125 level were decreased significantly( P〈 0.05). Conclusions: LNG-IUD is a safe, effective and simple treatment of adenomyosis in pedmenopausal period.
出处 《实用妇产科杂志》 CAS CSCD 北大核心 2009年第12期746-747,共2页 Journal of Practical Obstetrics and Gynecology
关键词 左炔诺酮宫内节育器 子宫腺肌病 围绝经后期 Levonorgestrel-releasing intrauterine device Adenomyosis Perimenopausal period
  • 相关文献

参考文献10

  • 1Ingrid C, Duncan M, Andrea F. Actigraphy quantifies reduced voluntary physical activity in women with primary dysmenorrhea [J]. The Journal of Pain, 2009,10(1): 38-46.
  • 2陈春林,刘萍,吕军,余莉萍,马奔,王锦江,刘佩鸣.子宫动脉栓塞术在子宫腺肌病治疗中的应用[J].中华妇产科杂志,2002,37(2):77-79. 被引量:139
  • 3Kim MD , Won JW, Lee DY, et al. Uterine artery embolization for adenomyosis without fibroids [J]. Clin Radiol,2004,59 (6):520- 526.
  • 4Luukkainen T, Lahteenmaki P, Toivonen J. Levonorgestrel-releasing intrauterine device [J]. Ann Med, 1990,22 (2) :85 - 90.
  • 5Lockhat FB, Emembolu JE, Konje J. Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel [J]. Fertil Steril, 2005,83(2) :398 - 404.
  • 6Hurskainen R, Salmi A, Paavonen J, et al. Expression of sex steroid receptors and Ki-67 in the endometria of menorrhagic women: effects of intranterine levonorgestrel [J]. Mol Hum Reprod, 2000, 6 ( 11 ) : 1013 - 1018.
  • 7McGavigan CJ, Dockery P, Metaxa-Mariatou V. Honnonally mediated disturbance of angiogenesis in the human endometrium after exposure to intrauterine levonorgestrel [ J]. Hum Reprod, 2003,18( 1 ) : 77 - 84.
  • 8Bragheto AM, Caserta N, Bahamondes L, et al. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging [J]. Contraception,2007,76(3) : 195 - 199.
  • 9Cho S, Nam A, Kim H, et al. Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis [J]. Am J Obstet Gynecol, 2008,198(4) :373 - 374.
  • 10Tinna Backman. Benefit-risk assessment of the levonorgestrel intrauterine system in contraception [J]. Drug salty,2004,27(15) : 1185 - 1204.

二级参考文献3

共引文献138

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部